Background
Applied
Type
ModificationConfidence
88%
Created
Apr 19, 2026
Evidence
1 source
Rationale
The stale ESVS citation was replaced with the superseding ESVS 2024 guideline ESVS in both instances where it appeared, as the newer guideline covers the same claims (AAA prevalence and screening/surveillance recommendations). No other content changes were warranted; the existing text remains accurate and well-structured.
Evidence
Content Changes
removedadded
Aneurysmal disease spans abdominal ([[abdominal aortic aneurysm (AAA)]]), thoracic ([[TAA]]), thoracoabdominal ([[TAAA]]), and peripheral arterial beds [@esc2014] and remains a leading cause of sudden vascular death due to rupture. AAA prevalence in men ≥65 years is approximately 1.5–4.5% [@esvs2024-editors][@esvs2024] and lower in women, who have higher rupture risk at smaller diameters [@svs2018]. Thoracic aneurysms are less common but carry high lethality, particularly in connective tissue disorders (Marfan, Loeys–Dietz, vascular Ehlers–Danlos) [@esc2014]. Peripheral aneurysms (popliteal, femoral, visceral, renal) often coexist with AAA [@dawson1997]. Population screening of older men reduces AAA-related mortality and emergent repairs, and contemporary guidelines define who to screen and how to surveil detected AAAs [@mass2002] [@svs2018] [@esc2014] [@esvs2024-editors].[@esvs2024]. For peripheral arterial disease management, see [[PAD]].